Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
What do we know about SARS-CoV-2 transmission?.
Meylan, P..
Revue Medicale Suisse ; 16(712):2078-2079, 2020.
Article in French | EMBASE | ID: covidwho-20239707
2.
Origin of SARS-CoV-2: The probable and the possible.
Meylan, P..
Revue Medicale Suisse ; 16(691):875, 2020.
Article in French | EMBASE | ID: covidwho-20239706
3.
Mutation in the SARS-CoV-2 spike protein.
Meylan, P..
Revue Medicale Suisse ; 16(701):1470, 2020.
Article in French | EMBASE | ID: covidwho-20239705
4.
Fourth dose of COVID vaccine: What do you think?
Meylan, P..
Revue Medicale Suisse ; 18(783):1082-1083, 2022.
Article in French | EMBASE | ID: covidwho-1970069
5.
Clinical severity of COVID caused by the omicron variant
Meylan, P..
Revue Medicale Suisse ; 18(780):918-919, 2022.
Article in French | EMBASE | ID: covidwho-1918405
6.
Safety of the mRNA COVID-19 vaccine in pregnant women: Preliminary results
Meylan, P..
Revue Medicale Suisse ; 17(738):950-951, 2021.
Article in French | EMBASE | ID: covidwho-1897449
7.
The subversive strategies used by SARS-CoV-2 to suppress host defenses
Meylan, P..
Revue Medicale Suisse ; 16(714):2190-2191, 2020.
Article in French | EMBASE | ID: covidwho-1897439
8.
Decreased humoral immune response to Pfizer-Biontech vaccine (BNT162b2) over 6 months
Meylan, P..
Revue Medicale Suisse ; 17(758):1954-1955, 2021.
Article in French | EMBASE | ID: covidwho-1880583
9.
Severite clinique du Covid cause par le variant omicron
Meylan, P..
Revue Medicale Suisse ; 18(780):918-919, 2022.
Article in French | MEDLINE | ID: covidwho-1836682
10.
Waning immunity after vaccination with Pfizer-BioNTech (BNT162b2) in Israel
Meylan, P..
Revue Medicale Suisse ; 17(759):2014-2015, 2021.
Article in French | EMBASE | ID: covidwho-1819201
11.
Waning immune humoral response to Pfizer-BioNtech vaccine (BNT162b2) over 6 months
Meylan, P..
Revue Medicale Suisse ; 17(758):1954-1955, 2021.
Article in French | EMBASE | ID: covidwho-1819200
12.
Protection contre le Covid-19 apres rappel (booster) par le vaccin Pfizer/BioNTech (BNT162b2)
Meylan, P..
Revue Medicale Suisse ; 17(762):2154-2155, 2021.
Article in French | MEDLINE | ID: covidwho-1557923
13.
Decroissance de l'immunite apres vaccination par Pfizer-BioNTech (BNT162b2) en Israel
Meylan, P..
Revue Medicale Suisse ; 17(759):2014-2015, 2021.
Article in French | MEDLINE | ID: covidwho-1519009
14.
Diminution de la reponse immunitaire humorale au vaccin Pfizer-BioNtech (BNT162b2) sur 6 mois
Meylan, P..
Revue Medicale Suisse ; 17(758):1954-1955, 2021.
Article in French | MEDLINE | ID: covidwho-1507161
15.
Securite du vaccin a ARNm BNT162b2 (Pfizer) en etude de phase 4
Meylan, P..
Revue Medicale Suisse ; 17(756):1858-1859, 2021.
Article in French | MEDLINE | ID: covidwho-1489085
16.
A guide to limit airborne transmission of COVID-19 in indoor spaces
Meylan, P..
Revue Medicale Suisse ; 17(748):1482-1483, 2021.
Article in French | Scopus | ID: covidwho-1411294
17.
Covid-19: guide pour limiter la transmission aeroportee dans les espaces interieurs
Meylan, P..
Revue Medicale Suisse ; 17(748):1482-1483, 2021.
Article in French | MEDLINE | ID: covidwho-1380286
18.
Efficacy and safety of BioNTech/Pfizer and Moderna vaccines
Meylan, P..
Revue Medicale Suisse ; 17(720-721):107-108, 2021.
Article in French | EMBASE | ID: covidwho-1368284
19.
COVID-19: Characteristics and duration of antibody responses and their relationship to disease severity
Meylan, P..
Revue Medicale Suisse ; 17(724):278, 2021.
Article in French | EMBASE | ID: covidwho-1368283
20.
Safety and efficacy of the Oxford-AstraZeneca vaccine: Interim analysis of four randomized controlled trials
Meylan, P..
Revue Medicale Suisse ; 17(726):366-367, 2021.
Article in French | EMBASE | ID: covidwho-1368282
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL